NASDAQ:INVA Innoviva (INVA) Stock Price, News & Analysis → Look Who Fired the World’s Richest Man (From Banyan Hill Publishing) (Ad) Free INVA Stock Alerts $16.11 -0.08 (-0.49%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$15.77▼$16.5250-Day Range$14.40▼$16.1952-Week Range$12.22▼$16.86Volume747,548 shsAverage Volume661,318 shsMarket Capitalization$1.02 billionP/E Ratio7.26Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Innoviva alerts: Email Address Innoviva MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish18.39% of Float Sold ShortDividend StrengthN/ASustainability-0.33Upright™ Environmental ScoreNews Sentiment0.82Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.33 out of 5 starsMedical Sector2283rd out of 2,771 stocksPharmaceutical Preparations Industry1073rd out of 1,288 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Innoviva.Read more about Innoviva's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.39% of the float of Innoviva has been sold short.Short Interest Ratio / Days to CoverInnoviva has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in Innoviva has recently decreased by 1.48%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldInnoviva does not currently pay a dividend.Dividend GrowthInnoviva does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInnoviva has received a 60.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private equity funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for Innoviva is -0.33. Previous Next 3.2 News and Social Media Coverage News SentimentInnoviva has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Innoviva this week, compared to 1 article on an average week.Search Interest4 people have searched for INVA on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innoviva insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Innoviva is held by insiders.Percentage Held by Institutions99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Innoviva's insider trading history. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Innoviva is 7.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.23.Price to Earnings Ratio vs. SectorThe P/E ratio of Innoviva is 7.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 159.20.Price to Book Value per Share RatioInnoviva has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Innoviva's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden to Drop BOMBSHELL June 13th?Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th!Click here now to see his shocking evidence. About Innoviva Stock (NASDAQ:INVA)Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Read More INVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVA Stock News HeadlinesMay 10, 2024 | finance.yahoo.comInnoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed AnalysisMay 10, 2024 | finance.yahoo.comInnoviva First Quarter 2024 Earnings: EPS: US$0.58 (vs US$0.51 in 1Q 2023)May 8, 2024 | investorplace.comINVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | businesswire.comInnoviva to Participate in the BofA Securities Health Care ConferenceApril 24, 2024 | finance.yahoo.comInnoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024April 24, 2024 | businesswire.comInnoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024April 22, 2024 | finance.yahoo.comShould Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?March 8, 2024 | benzinga.comInsider Decision Unfolding At Innoviva: Pavel Raifeld Exercises OptionsMarch 4, 2024 | msn.comArmata enters $35M credit agreement with InnovivaFebruary 29, 2024 | finance.yahoo.comInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressFebruary 29, 2024 | businesswire.comInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressFebruary 28, 2024 | msn.com10 stocks you can bet on being inflation-proofFebruary 14, 2024 | finance.yahoo.comJim Simons Bolsters Position in Innoviva Inc with Recent AcquisitionFebruary 8, 2024 | morningstar.comInnoviva Inc INVAFebruary 6, 2024 | morningstar.comCosmo Pharmaceuticals NV COPNJanuary 25, 2024 | stocknews.com3 Lucrative Biotech Stock Buys for SuccessJanuary 8, 2024 | msn.comChart of the Day: Innoviva - Individual Investor FavoriteDecember 30, 2023 | finance.yahoo.comInnoviva's (NASDAQ:INVA) investors will be pleased with their 29% return over the last three yearsDecember 21, 2023 | uk.finance.yahoo.comInnoviva, Inc. (INVA) stock historical prices & data – Yahoo FinanceDecember 11, 2023 | stocknews.comAnalyzing the Bullish Opportunities of 3 Biotech StocksNovember 27, 2023 | msn.comInnoviva (INVA) Price Target Increased by 7.14% to 15.30November 18, 2023 | finance.yahoo.comInsider Sell Alert: Marianne Zhen Offloads Shares of Innoviva IncNovember 14, 2023 | finance.yahoo.comInnoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?November 3, 2023 | finance.yahoo.comInnoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 MillionNovember 1, 2023 | finance.yahoo.comPositive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated GonorrheaSee More Headlines Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today5/14/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees112Year Founded1996Profitability EPS (Most Recent Fiscal Year)$2.22 Trailing P/E Ratio7.28 Forward P/E RatioN/A P/E GrowthN/ANet Income$179.72 million Net Margins58.21% Pretax Margin63.57% Return on Equity28.94% Return on Assets15.39% Debt Debt-to-Equity Ratio0.63 Current Ratio10.42 Quick Ratio9.17 Sales & Book Value Annual Sales$310.46 million Price / Sales3.29 Cash Flow$3.63 per share Price / Cash Flow4.46 Book Value$10.66 per share Price / Book1.52Miscellaneous Outstanding Shares63,230,000Free Float62,342,000Market Cap$1.02 billion OptionableOptionable Beta0.57 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Pavel Raifeld C.F.A. (Age 40)Chief Executive Officer Comp: $754.67kMs. Marianne Zhen CPA (Age 55)Chief Accounting Officer & Secretary Comp: $530.21kMr. Stephen Basso M.B.A. (Age 58)Chief Financial Officer Key CompetitorsOPKO HealthNASDAQ:OPKMannKindNASDAQ:MNKDIronwood PharmaceuticalsNASDAQ:IRWDLigand PharmaceuticalsNASDAQ:LGNDPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInsiders & InstitutionsCANADA LIFE ASSURANCE CoBought 2,242 shares on 5/14/2024Ownership: 0.078%American International Group Inc.Sold 923 shares on 5/14/2024Ownership: 0.050%O Shaughnessy Asset Management LLCBought 38,080 shares on 5/13/2024Ownership: 0.116%Bessemer Group Inc.Bought 1,701 shares on 5/13/2024Ownership: 0.003%Hillsdale Investment Management Inc.Bought 24,900 shares on 5/11/2024Ownership: 0.499%View All Insider TransactionsView All Institutional Transactions INVA Stock Analysis - Frequently Asked Questions How have INVA shares performed in 2024? Innoviva's stock was trading at $16.04 at the start of the year. Since then, INVA stock has increased by 0.4% and is now trading at $16.11. View the best growth stocks for 2024 here. When is Innoviva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our INVA earnings forecast. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings results on Thursday, February, 29th. The biotechnology company reported $0.76 EPS for the quarter. The biotechnology company had revenue of $85.84 million for the quarter. Innoviva had a net margin of 58.21% and a trailing twelve-month return on equity of 28.94%. What ETFs hold Innoviva's stock? ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), Invesco Pharmaceuticals ETF (PJP), Harbor Health Care ETF (MEDI), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Conductor Global Equity Value ETF (CGV), SPDR S&P Pharmaceuticals ETF (XPH) and Roundhill Acquirers Deep Value ETF (DEEP). What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). Who are Innoviva's major shareholders? Innoviva's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.94%), Westfield Capital Management Co. LP (3.34%), Denali Advisors LLC (0.52%), Principal Financial Group Inc. (0.51%), Hillsdale Investment Management Inc. (0.50%) and Empowered Funds LLC (0.40%). Insiders that own company stock include Alexander J Denner, George Bickerstaff, Innoviva, Inc, Marianne Zhen, Pavel Raifeld and Plc Glaxosmithkline. View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INVA) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe only AI company you should be looking atBehind the MarketsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.